GlaxoSmithKline (GSK) Misses Q4 EPS by 26c

GlaxoSmithKline (NYSE: GSK) reported Q4 EPS of GBP0.23, GBP0.26 worse than the analyst estimate of GBP0.49. Revenue for the quarter came in at GBP8.12 billion versus the consensus estimate of GBP9.86 billion.

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.

You May Also Be Interested In

• Best Buy (BBY) Tops Q2 EPS by 12c, Offers Guidance
• e.l.f. Beauty (ELF) PT Raised to $123 at Canaccord
• Dollar General (DG) Tops Q2 EPS by 48c, Beats on Revenue; Offers FY27 EPS Guidance